http://www.aidsmap.com/CROI-2013-news/page/2571834/ en-gb NAM Publications - 2013 Fri, 22 Mar 2013 09:56:54 GMT Fri, 22 Mar 2013 09:56:54 GMT http://backend.userland.com/rss RSS.NET: http://www.rssdotnet.com/ Offering people the opportunity to self-test at home and then start antiretroviral therapy after counselling at home, together with home delivery of antiretroviral drugs, increased the number of people linked to care after testing and started on treatment almost threefold, a randomised study in Malawi has shown. The findings, presented last week at the 20th Conference http://www.aidsmap.com/Self-testing-and-home-treatment-initiation-triples-uptake-of-HIV-treatment-in-Malawi/page/2605852/ CROI CROI 2013 Malawi Promoting HIV testing Retention and linkage to care Starting treatment Keith Alcorn http://www.aidsmap.com/page/2605852/ Thu, 21 Mar 2013 08:30:00 GMT A simple 24-week oral regimen consisting of sofosbuvir plus full-dose ribavirin cured nearly 70% of previously untreated people with genotype 1 hepatitis C, many of whom had factors predictive of poor response, researchers reported last week at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta. Direct-acting antiviral agents that target various steps of the hepatitis C virus (HCV) http://www.aidsmap.com/Sofosbuvir-plus-ribavirin-works-well-for-hard-to-treat-inner-city-hepatitis-C-patients/page/2605337/ CROI CROI 2013 Delivery of care New and experimental hepatitis C treatment United States Liz Highleyman http://www.aidsmap.com/page/2605337/ Wed, 20 Mar 2013 07:40:00 GMT All-oral regimens consisting of the HCV protease inhibitor ABT-450, a non-nucleoside polymerase inhibitor and ribavirin led to sustained response for more than 90% of previously untreated hepatitis  C patients – including those with unfavourable IL28B gene patterns – but only about half of prior non-responders, researchers reported earlier this month at the 20th Conference on Retroviruses and Opportunistic http://www.aidsmap.com/AbbVie-interferon-free-combinations-cure-most-newly-treated-hepatitis-C-patients/page/2605367/ CROI CROI 2013 New and experimental hepatitis C treatment United States Liz Highleyman http://www.aidsmap.com/page/2605367/ Wed, 20 Mar 2013 07:30:00 GMT Several presentations at the recent 20th Conference on Retroviruses and Opportunistic Infections in Atlanta suggest that previous estimates of the proportion of people with HIV in the USA who are on antiretroviral therapy (ART) and with an undetectable viral load may have been too low and may be closer to the proportion virally suppressed http://www.aidsmap.com/Are-we-underestimating-the-proportion-of-virally-suppressed-patients-in-the-US/page/2600686/ CROI Access to medicines and treatment CROI 2013 France France Infectiousness and treatment as prevention New York Retention and linkage to care Seattle Structural factors United Kingdom United Kingdom United States Gus Cairns http://www.aidsmap.com/page/2600686/ Fri, 15 Mar 2013 08:10:00 GMT A ritonavir-boosted lopinavir (LPV/r)-based regimen achieved a comparable rate of virologic suppression when compared to a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimen in HIV-infected Ugandan children at 48 weeks, with comparable immunological responses and adverse events, researchers reported at the 20th Conference on Retroviruses and Opportunistic Infections(CROI 2013) last week in Atlanta. These findings from the Prevention http://www.aidsmap.com/Lopinavirritonavir-equivalent-to-nevirapine-in-Ugandan-children/page/2598853/ CROI CROI 2013 HIV treatment in children Malaria Carole Leach-Lemens http://www.aidsmap.com/page/2598853/ Thu, 14 Mar 2013 10:00:00 GMT Gene therapy approaches that involve the genetic modification of human haematopoietic stem cells have the potental to engineer HIV control by introducing cells resistant to HIV infection, the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) heard last week. The proof of concept for this approach to HIV control http://www.aidsmap.com/Gene-therapy-studies-show-potential-for-HIV-control-without-drugs/page/2595253/ CROI CROI 2013 New and experimental HIV treatments The search for a cure United States Vaccines Gus Cairns http://www.aidsmap.com/page/2595253/ Wed, 13 Mar 2013 06:50:00 GMT Adding telaprevir (Incivo or Incivek) to pegylated interferon and ribavirin shortens the duration of treatment and increases the likelihood of a cure for HIV-positive men with acute sexually transmitted hepatitis C virus (HCV), according to study findings presented last week at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta. Since the early 2000s, researchers have reported outbreaks of http://www.aidsmap.com/Adding-telaprevir-improves-acute-hepatitis-C-treatment-for-HIV-positive-men/page/2597723/ CROI CROI 2013 New and experimental hepatitis C treatment United States Liz Highleyman http://www.aidsmap.com/page/2597723/ Tue, 12 Mar 2013 17:30:00 GMT An all-oral combination of simeprevir plus sofosbuvir, with or without ribavirin, led to an early cure for most hard-to-treat prior null responders with genotype 1 hepatitis C studied in the phase 2a COSMOS trial, according to a presentation last week at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta. The advent of http://www.aidsmap.com/Simeprevir-sofosbuvir-demonstrates-good-early-cure-rate-with-or-without-ribavirin/page/2597301/ CROI CROI 2013 New and experimental hepatitis C treatment United States Liz Highleyman http://www.aidsmap.com/page/2597301/ Tue, 12 Mar 2013 12:20:00 GMT Eighteen months after implementation of 'Option B+' in Malawi – ART for life for all HIV-infected, pregnant or breastfeeding women regardless of CD4 count or disease stage – the number of HIV-infected pregnant women on ART increased dramatically (763%), with retention rates at twelve months (78%) comparable to that in other adults (81%), http://www.aidsmap.com/Malawi-achieves-seven-fold-increase-in-ART-for-pregnant-and-breastfeeding-women/page/2596284/ CROI CROI 2013 Delivery of care Malawi Prevention of mother-to-child transmission Treatment guidelines Carole Leach-Lemens http://www.aidsmap.com/page/2596284/ Tue, 12 Mar 2013 12:10:00 GMT Six-monthly viral load testing of patients taking antiretroviral therapy (ART) at primary health clinics in rural Kenya reduced the risk of virologic failure at 18 months of follow-up by 46%, according to the results of the Clinic-based ART Diagnostic Evaluation (CLADE) randomised controlled trial conducted in rural Kenya at seven district-level clinics. Dr Frederick http://www.aidsmap.com/Routine-viral-load-monitoring-almost-halves-risk-of-virologic-failure-in-18-month-Kenyan-study/page/2596417/ CROI CROI 2013 Health monitoring in resource-limited settings Kenya Viral load Lesley Odendal http://www.aidsmap.com/page/2596417/ Tue, 12 Mar 2013 06:30:00 GMT